Depresyon hastalarında reboksetin ve venlafaksinin EKG değişkenleri üzerine etkisi Amaç: Antidepresanlar reseptör özelliklerine göre kardiak otonomik sinir sistemi işleyişi üzerine farklı etkiler göstere-bilir. Bu nedenle farklı gruplardaki antidepresanların deği-şen boyutlarda kardiak değerleri etkilemesi beklenebilir. Bu çalışma bir serotonin ve noradrenalin geri alım inhibitörü olan venlafaksin ile bir seçici noradrenalin geri alım inhibitörü olan reboksetinin elektrokardiyografi (EKG) değerleri ve yaşamsal bulgular üzerine etkilerini karşılaştırmaktadır. Yöntem: Major depresif bozukluk tanısı ile izlenen 44 hastanın kardiak parametreleri ve yaşamsal bulguları değerlendirildi. Venlafaksinin başlangıç dozu 75 mg/ gün, reboksetinin başlangıç dozu 4 mg/gün iken her iki ilacın dozları 2. hafta itibariyle sırasıyla 150 mg/gün ve 8 mg/ gün'e çıkıldı. Çalışmanın başında ve sonunda hastaların EKG'leri çekildi ve PR, QRS, QT ve QTc değerleri ile yaşamsal bulgular kayıt edildi. Sonuçlar: çalışma sonunda reboksetin grubunda kalp hızı-nın belirgin olarak yükseldiği saptandı (Wilcoxon z=-3.510, p<0.001). Çalışma sonunda venlafaksin grubunda EKG değerlerinde değişiklik izlenmezken, reboksetin grubunda QT aralığının belirgin olarak kısaldığı (Wilcoxon z=-2.157, p=0.031) ve QTc aralığının belirgin olarak uzadığı saptandı (Wilcoxon z=-2.399, p=0.016). Venlafaksin grubunda diyastolik kan basıncının (yatar durumda) çalışma sonunda belirgin olarak yükseldiği saptandı. (Wilcoxon z=-2.390, p=0.017). Tartışma: Her antidepresanın farklı reseptör özellikleri olduğundan kardiak değerler üzerine farklı etkilerinin olması muhtemeldir. Bir seçici noradrenerjik antidepresan olan reboksetinin çift etkili venlafaksine göre kardiak değerleri daha çok etkilediği söylenebilir. Bununla beraber, etki etme düzenekleri açısından farklılıklar gösteren antidepresanların kardiak etkileri geniş ölçekli çalışmalarla ayrıntılı olarak araştırılmalıdır. The effects of reboxetine and venlafaxine on ECG variables in depressed patients Objective: Antidepressants exert distinct effects on cardiac autonomic nervous system function depending on their receptor profile; thus, different groups of antidepressants are expected to influence cardiac parameters in varying degrees. This study compares the effects of venlafaxine, a serotonin and noradrenaline reuptake inhibitor and reboxetine, a selective noradrenaline reuptake inhibitor, on ECG parameters and vital signs. Methods: The cardiac parameters and vital signs of 44 depressed patients were evaluated. The initial dose of venlafaxine XR was 75 mg/day and the dose was increased to 150 mg/day at the end of the 2 nd week. Reboxetine was started at 4 mg/day and increased to 8 mg/day at the end of the 2 nd week of the study. Electrocardiography (ECG) was performed and the PR, QRS, QT, and QTc intervals were measured both at the beginning and at the end of the trial, as were the vital signs. Results: The heart rate was significantly increased in the reboxetine group (Wilcoxon z=-3.510, p<0.001). The ECG parameters did not demonstrate significant differences at the end of the trial in the venlafaxine group, whereas the QT interval was significantly shortened (Wilcoxon z=-2.157, p=0.031) and the QTc interval significantly prolonged (Wilcoxon z=-2.399, p=0.016) in the reboxetine group at the end of the trial. Diastolic blood pressure (supine) was significantly increased at the end of the trial (Wilcoxon z=-2.390, p=0.017) in the venlafaxine group. Conclusions: Since antidepressants have distinct receptor profiles, they may have varying effects on cardiac parameters. Reboxetine, a selective noradrenergic drug, is more likely to influence cardiac parameters than venlafaxine, a dual acting drug. Different groups of antidepressants, based on their mechanisms, of action should be studied more extensively with regard to their cardiac effects. 
INTRODUCTION
Major depressive disorder (MDD) patients are reported to have increased risk for cardiac pathologies such as ventricular tachycardia (1, 2) , heart rate variability (3) , and cardiac mortality (4) , even though some contradictory reports exist (5) . The underlying mechanisms for cardiac pathologies in MDD are related to an impaired parasympathetic autonomic nervous system, which eventually causes reduced heart rate variability (6) , increased QT variability (7) and increased platelet activity (8) .
To date extensive studies have been conducted regarding the cardiac safety of various antidepressants (9) (10) (11) . Cardiovascular effects of selective serotonin reuptake inhibitors (SSRI) are believed to be safe so far. They are associated with slow pulse rate, but have little or no effect on PR, QRS, and QTc intervals (12, 13) .
Although the accumulated data on the cardiovascular effects of venlafaxine, a serotonin and noradrenaline reuptake inhibitor, are limited, studies have demonstrated that administration of venlafaxine is safe regarding its cardiovascular effects even at high doses (13, 14) ; however, QTc interval prolongation (15) and fatal cardiotoxicity induced by venlafaxine overdosing (17) have been reported. Furthermore, systematic monitoring of cardiovascular parameters during treatment with venlafaxine has been strongly recommended due to undesirable cardiovascular side effects particularly in the elderly (18) . Although the evidence is scarce on the cardiovascular effects of reboxetine, a selective noradrenaline reuptake inhibitor, it has been found to have no significant effect on prolongation of the QTc interval (19) .
Venlafaxine is an antidepressant with a dual action, blocking reuptake of both serotonin and noradrenaline at therapeutic doses (20) . At high doses it also has a weak dopamine reuptake blocking effect (21) . Reboxetine is a selective noradrenaline reuptake inhibitor (22) . Both of these antidepressants are effective in treating depression (23, 24) .
In the present study we aimed to compare the effects of venlafaxine and reboxetine, which exert their antidepressant effects through different mechanisms of action, on both ECG parameters and vital signs.
METHODS

Patient population
Subjects were recruited from the database of a previous study which compared reboxetine and venlafaxine in terms of efficacy and tolerability (25) . Patients were 18-65 years of age, diagnosed with MDD, as determined on the basis of the Diagnostic and Statistical Manual of Mental Disorders, fourth edition, Text Revision (DSM-IV-TR), and eligible for participation in the present study. Patients with any clinically significant medical disorder or laboratory abnormality and patients with a history of substance abuse within a year were not eligible for participation in the study. Patients with disturbances of cardiac rate and rhythm, QTc interval greater than 470 ms in the ECG performed at baseline, alterations of hepatic or renal functions or with a diagnosis of substance abuse were also excluded from the study.
Study design
Throughout the study the patients were assessed 6 times; on the day of the screening visit (-7 th day), at baseline or the first visit (day 0), and on the 14 th (visit 2), 28 th (visit 3), 49 th (visit 4) and 70 th (visit 5) day after the baseline. Physical examination and laboratory tests, including biochemical, blood and urine analysis and complete blood count were carried out and vital signs (body temperature, blood pressure and heart rate) were measured at the first visit and at the end of study. Electrocardiography (ECG) was performed and the PR, QRS, QT, and QTc intervals were measured both at the beginning and at the end of the trial. Diastolic blood pressure (DBP) and systolic blood pressure (SBP) were measured in supine and standing positions after at least 15 minutes of rest. All tests were performed between 09:00-09:30 AM. All patients were drug free during the screening visit. The study protocols were approved by the relevant ethics committees and were conducted in accordance with the Declaration of Helsinki. All subjects gave written informed consent to participate in the study.
Drug administration
Patients who met the study inclusion criteria were randomly assigned to venlafaxine XR capsules or reboxetine tablets. Both reboxetine and venlafaxine are known to be effective and tolerable in the treatment of MDD (24, 26) . The initial dose of venlafaxine XR was 75 mg/day and was increased to 150 mg/day at the end of 2nd week. Reboxetine was started with 4 mg/day and the dose was increased to 8 mg/day at the end of the 2nd week of the study. The doses remained at those levels throughout the study. At the end of the 11 th week, the study was completed. Patients were not allowed to take concomitant medications; however, in cases of sleep disturbance or increased anxiety, patients were allowed to take low doses of hydroxyzine (12.5 mg/day) when required. The study was designed as an open-label, randomized, retrospective study; thus researchers and patients were not blind to the study drugs.
ECG recording and measurements
The ECGs were obtained by a standard 3-lead resting ECG procedure in the supine position and analyzed by a cardiologist who was blind to the patient's condition, study hypothesis, treatment status, and administered antidepressants and was not involved in the care of the patients. The QTc interval was calculated with the Bazett formula. The QT interval was assessed in both DII and V2 leads. It was decided to focus on the DII lead measurements due to the higher variability of measurements in precordial leads. The QT interval was measured from the beginning of the QRS complex to the end of the T wave in the lead with the longest interval and without prominent U waves. The result was a computation of the corrected QT interval using the following equation: QTc=QT/(R-R)1/2.
Statistical Analysis
Statistical analyses were performed using SPSS for Windows 13 (SPSS Inc., Illinois, USA). Descriptive statistics were calculated and the measure of variability was given as mean±standard deviation. The homogeneity of groups with respect to pre-treatment values of vital signs and ECG parameters were studied. By using the Kolmogorov-Smirnov test, all variables, except for the age variable, the assumptions of normal distribution were not convenient. For time dependent variables, percent changes were computed. The independent samples t-test and Mann Whitney U test were used for group comparisons. Comparisons within groups were evaluated by the Wilcoxon signed ranks test. Fisher's exact test was used where there was a gender difference between the treatment groups.
RESULTS
A total of 53 patients were enrolled in the previous study. Seven of them were unable to complete the study protocol and 2 patient's ECGs were missing. Forty-four patients were evaluated in terms of ECG parameters and their vital signs.
There were 22 patients in the reboxetine group and 22 patients in the venlafaxine group. The mean age of the whole group was 40.1±11.9 years. There were no significant differences between the groups in terms of age, gender, basal values of heart rate, blood pressure, and ECG parameters. Heart rate was significantly increased in the reboxetine group at the end of the trial (Wilcoxon z=-3.510, p<0.001), but not in the venlafaxine group. SBP (standing and supine position) did not differ in the reboxetine or the venlafaxine group at the end of the study compared to the basal values. DBP (supine position) did not change in the reboxetine group, whereas in the venlafaxine group at visit 3 (Wilcoxon z=-2.746, p=0.006) and visit 5 (Wilcoxon z=-2.390, p=0.017) an increase was observed compared to the basal values. DBP (standing position) demonstrated a significant increase in the reboxetine group at visit 4 (Wilcoxon z=-2.194, p=0.028), but in the venlafaxine group an increase was observed at visit 3 (Wilcoxon z=-2.313, p=0.021) compared to the basal values.
When the two groups were compared with each other, no significant differences were found between the groups in terms of percent changes in body temperature, heart rate, and SBP (standing and supine position); however, percent changes in DBP (supine position) demonstrated a significant increase in the venlafaxine group at visit 3 (Mann-Whitney U z=-2.649, p=0.008) and DBP (standing) showed a significant increase in the venlafaxine group at visit 3 (Mann-Whitney U z=-2.089, p=0.037) compared to the reboxetine group.
ECG parameters did not demonstrate a significant difference at the end of the trial in the venlafaxine group, whereas the QT interval was significantly shortened (Wilcoxon z=-2.157, p=0.031) and the QTc interval significantly prolonged (Wilcoxon z=-2.399, p=0.016) in the reboxetine group at the end of the trial. ECG parameters did not differ between the treatment groups. Table 1 presents the values of ECG parameters at visits 1 and 5. Table 2 presents the values of blood pressure at visits 1 and 5.
DISCUSSION
The accumulated data regarding the effects of reboxetine and venlafaxine on cardiac parameters are rather scarce. One consistent finding is that heart rate is likely to increase with reboxetine treatment. The significant increase in heart rate with reboxetine treatment in this study is in line with previous studies (27, 28) . The accelerated heart rate had been previously attributed to the sympathomimetic activity of reboxetine (29) . On the other hand, there was a trend of association between venlafaxine and increased heart rate although this was not clinically or statistically significant. Likewise, Mbaya et al. (15) did not find accelerated heart rate with high doses of venlafaxine. Since it is known that venlafaxine may increase heart rate particularly at doses above 300 mg/day (30), we might have observed significant acceleration in heart rate if venlafaxine doses had been higher than 150 mg/day. None of the patients in the study population had tachycardia (≥120 bpm).
In the present study none of the treatments affected SBP, but DBP was significantly increased at visit 3 in venlafaxine group. This may have been related to the dose increase in venlafaxine at visit 2. Higher values of DBP might be expected if venlafaxine doses had been higher than 150 mg/day, since venlafaxine has been associated with increased blood pressure, particularly at high doses (30) . On the other hand, some clinical trials regarding the safety and tolerability of reboxetine, did not mention increased blood pressure (31) (32) (33) . In line with the findings of those trials, reboxetine treatment seemed unrelated to the alterations in BP except for the temporary increase in DBP (standing position) at visit 4. Unlike previously mentioned trials with reboxetine, Penttilä et al. (28) and Mayer et al. (34) reported significant increases in SBP, but not in DBP and a more recent article has suggested avoiding reboxetine in patients with hypertension (2). Another study by Denolle et al. (35) reported significant increases in SBP and DBP when healthy subjects were in the supine position but not when they were standing. They also suggested that the S, S-enantiomer might be responsible for the hemodynamic effects of reboxetine in humans. The QTc interval is considered to be a marker of the arrhythmogenic potential of a drug, specifically linked to an increased risk of ventricular tachycardia (36) . For men, QTc values over 0.45 sec and for women over than 0.47 sec are considered to be prolonged (37) . A QTc interval value over 0.50 sec is associated with an increased risk for torsades de pointes which may be fatal in some cases (36) and a QTc interval greater than 0.50 sec has been suggested as a clinically significant cut-off (38) . Tricyclic antidepressants, which have been used in the treatment of MDD for decades, are associated with adverse cardiovascular effects such as increased heart rate, orthostatic hypotension, and prolongation of the QTc interval (39, 40) . Although the SSRIs are also associated with QTc interval prolongation according to some authors (41, 42) , the potential risk for cardiotoxicity has been suggested as minimal compared to other groups of antidepressants (2) .
According to the clinical trial database analysis regarding the safety and tolerability of venlafaxine, standard doses of venlafaxine have been reported to cause no ECG changes (43) . On the other hand overdoses of venlafaxine have been associated with ECG changes (16, 44) resulting in fatal outcomes in some cases (17) ; thus, along with tricyclics and trazodone, venlafaxine has been suggested to be avoided in patients at risk of developing arrhythmia (2) . In the United Kingdom, the National Institute of Clinical Excellence (NICE) has recommended ECG monitoring for all patients on venlafaxine although the guidelines are based on grade C evidence (45) . Venlafaxine has been shown to block the fast inward sodium current (INa) in ventricular myocytes, in a concentration-dependent manner (46) . This effect could explain the QTc prolongation and proarrhythmia observed in some patients treated with venlafaxine. In the present study we did not find any impact on ECG parameters with 150 mg/day venlafaxine treatment. In line with our findings Emul et al. (14) using 75 mg/day and Mbaya et al. (15) using high doses of venlafaxine did not report any significant changes in ECG parameters. Nevertheless, we might have found significant changes on ECG parameters if venlafaxine doses had been higher than 150 mg/day.
The accumulated data regarding the effects of reboxetine on ECG parameters are rather scarce. Denolle et al. (35) reported that reboxetine and its R, R-enantiomer had no effect on ECG parameters in healthy male volunteers, confirming the absence of effects of reboxetine and its enantiomer on ventricular repolarization and atrial conduction. Other studies also reported no significant changes on ECG parameters with reboxetine treatment (19, 27) . The present study, however, revealed significant prolongation of the QTc interval and shortening of the QT interval with reboxetine treatment. The most likely explanation for the shortened QT interval is related to the increased heart rate in the reboxetine group. It is difficult to interpret the significant QTc interval prolongation in reboxetine treated patients because of the lack of studies in the literature.
To the best of our knowledge, no study has demonstrated an effect of reboxetine on QTc interval prolongation. In this regard, this is the first study to demonstrate a significant impact of reboxetine treatment on ECG parameters. The only study which has demonstrated insignificant QTc interval prolongation with reboxetine was carried out by Denolle et al. (35) . In the present study none of the patients had QTc interval prolongation over 0.50 sec or any cardiac abnormality during the trial both in the reboxetine and venlafaxine groups.
This study has several limitations. Most importantly it suffers from the weaknesses of the open label study design. It is open to bias and the findings should be replicated in a double blind study. The small patient number and the missing placebo arm are also major limitations of the present study. In addition, the lack of a placebo group should be kept in mind when interpreting the results. We were unable to check serum levels of each drug. The doses of venlafaxine administered in this study may also be considered low. An SSRI arm would also have been a valuable contribution to the design of this study. In the absence of a placebo or comparator, it is not possible to exclude completely the influence of other factors, e.g. subjective stress caused by the experimental setting which could have influenced the measurements during the study period. In the present study measured QT intervals were corrected by Bazett's formula; however, the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (47) guidance states that "Bazett's correction overcorrects at elevated heart rates and under corrects at heart rates below 60 bpm and hence is not an ideal correction". This might be considered as another limitation of the present study. Nevertheless, the present study is the first study demonstrating the impact of reboxetine treatment on ECG parameters. Although the present study was designed as an open label study, the cardiologist who evaluated the ECG parameters was blind to the study drugs, a fact that may be considered an advantage.
CONCLUSION
The main finding of this study is that reboxetine has a more significant impact on heart rate and ECG parameters than venlafaxine.
Tricyclic antidepressants have been associated with adverse cardiac effects such as increased heart rate, orthostatic hypotension, and prolongation of the QTc interval. With the introduction of newer antidepressants like SSRIs, dual acting antidepressants, and selective noradrenaline reuptake inhibitors, cardiac adverse events have become less pronounced. As the data have accumulated about these drugs, some recommendations and warnings have arisen in terms of cardiac adverse events, particularly in overdose or intoxication.
Clinicians should be aware of patient complaints that may mimic some psychiatric symptoms, such as recurrent episodes of fainting during stress or excitement, which may be evidence of a prolonged QTc interval. It would be wise to ask patients if they have had episodes of syncope, if they have relatives with long QT syndrome, or if they have relatives who have died suddenly at a young age.
The effects of reboxetine on cardiac sodium (INa) and potassium channels (IKr) should be studied extensively, both in vivo and in vitro, in future studies to clarify possible relationships with QTc interval prolongation.
Since antidepressants exert distinct effects on cardiac autonomic nervous system function through their receptor profile, different groups of antidepressants are expected to influence cardiac parameters in varying degrees. In this regard, future studies with larger samples should investigate and compare different classes of antidepressants with respect to their cardiac effects depending on their mechanism of action.
